Deborah Glasser: Nasdaq Bell Celebrating FDA Approval of Novel ITP Therapy
Deborah Glasser, Head of Specialty Care for Sanofi, shared a post on LinkedIn:
”Yesterday, I had the opportunity to ring the Nasdaq closing bell, surrounded by Sanofi colleagues and representatives from the Platelet Disorder Support Association – PDSA. I’m so grateful that PDSA joined us on this special occasion to celebrate ITP Awareness Month, and to recognize the recent FDA approval of a novel treatment. By targeting root causes through multi-immune modulation, this new medicine represents a significant step forward for patients living with immune thrombocytopenia (ITP), a complex immune dysregulation disease, which can cause symptoms that disrupt daily life.
This moment reflects the power of science, collaboration, and our shared commitment to improving patient outcomes. At Sanofi, we continue to push the boundaries of immunoscience to make a meaningful difference for individuals affected by rare conditions like ITP.”
Stay updated with Hemostasis Today.
-
Apr 8, 2026, 17:04Heghine Khachatryan: Marfan vs LDS – Not All Aortopathies Are the Same
-
Apr 8, 2026, 17:00Frits Rosendaal Receives ISTH Grant Medal for Lifetime Contributions to Thrombosis and Hemostasis Field
-
Apr 8, 2026, 16:25Xiaoying Chen: Teleneurological Ward As A Practical Way to Support High-Quality Stroke Care Beyond Major Centres
-
Apr 8, 2026, 16:24Ney Carter Borges: Endocrine Drivers of Resistant Hypertension – Insights from the MOMENTUM Trial at ACC 26
-
Apr 8, 2026, 16:21Jonathan Gelber: Exploring Papaya Extract as an Option to Elevate Platelet Numbers Before PRP
-
Apr 8, 2026, 16:21Marilena Vrana: Take Our New Global Survey on Patient Experiences with Plasma-Derived Medicines
-
Apr 8, 2026, 16:19Jaideep Patel: Are We Underestimating Heart Disease Risk in South Asians?
-
Apr 8, 2026, 16:16Hans Middelhoven: HARMONICS – Improving Stroke Care Outcomes in Spain and Portugal
-
Apr 8, 2026, 16:16Tiffany Hall: HerCare – the Ultimate ‘BOGO’ in Maternal Health